About EOS Milano
EOS Milano is a company based in Milano (Italy) founded in 2005 was acquired by Clovis Oncology in November 2013.. EOS Milano has raised $17.23 million across 2 funding rounds from investors including Sofinnova, Aescap and Principia SGR. EOS Milano operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Milano, Italy
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.23 M (USD)
in 2 rounds
-
Latest Funding Round
$17.23 M (USD), Series A
Jul 30, 2009
-
Investors
Sofinnova
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Clovis Oncology
(Nov 19, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of EOS Milano
EOS Milano has successfully raised a total of $17.23M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.23 million completed in July 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $17.2M
- First Round First Round
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2009 | Amount | Series A - EOS Milano | Valuation |
investors |
|
| Jun, 2006 | Amount | Seed - EOS Milano | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EOS Milano
EOS Milano has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Sofinnova, Aescap and Principia SGR. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences sector focused early stage VC firm investing primarily in Europe
|
Founded Year | Domain | Location | |
|
Aescap is focused on investing in high-growth biotech companies.
|
Founded Year | Domain | Location | |
|
Early-stage investments in Italian tech and life sciences are targeted.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EOS Milano
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EOS Milano
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eos Milano Comparisons
Competitors of EOS Milano
EOS Milano operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eos Milano
Frequently Asked Questions about EOS Milano
When was EOS Milano founded?
EOS Milano was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Where is EOS Milano located?
EOS Milano is headquartered in Milano, Italy.
Is EOS Milano a funded company?
EOS Milano is a funded company, having raised a total of $17.23M across 2 funding rounds to date.
What does EOS Milano do?
Ethical Oncology Science (EOS) was founded in 2005 in Milano, Italy, as a biopharmaceutical company focused on oncology. Cancer treatments were advanced through the development of Lucitanib, an oral small-molecule tyrosine kinase inhibitor targeted at preventing new blood vessel formation in tumors and disrupting growth in FGF-dependent cancers. Phase III clinical trials were conducted for this compound. The company was acquired by Clovis Oncology in November 2013.
Who are the top competitors of EOS Milano?
EOS Milano's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are EOS Milano's investors?
EOS Milano has 4 investors. Key investors include Sofinnova, Aescap, Principia SGR, and Clovis Oncology.